Your Electrolytes Look Fine, Yet Your Heart Struggles. Here's Why.

Your APOE gene encodes a protein that binds to lipoproteins (the particles that carry cholesterol in your blood) and helps your cells absorb them. Think of it as the shipping label on a cholesterol package: it tells your cells where to send the cargo. Without APOE, cholesterol would just circulate indefinitely. There are three main versions of this gene: e2, e3, and e4. Most people carry some combination of these alleles.

If you carry the e4 allele, roughly 25% of people with European ancestry do, your cells are less efficient at clearing LDL from your bloodstream. Your body produces the same amount of cholesterol as everyone else, but it takes longer for your cells to pull it out of circulation. That means your LDL lingers in your blood longer, creating more opportunity for oxidation and plaque formation in your arteries.

You might notice that your cholesterol stays slightly elevated despite a clean diet. Or you might go years with normal cholesterol and then suddenly see a jump in your 40s or 50s. People with APOE e4 often find that diet alone doesn’t control their lipid levels the way it does for e2 or e3 carriers. They frequently need either medication or more aggressive dietary intervention earlier than guidelines suggest.

Your MTHFR gene produces the enzyme methylenetetrahydrofolate reductase. This enzyme is a bottleneck in a critical pathway: it converts dietary folate (from spinach, leafy greens, supplements) into the active form your cells actually use. That active form drives the methylation cycle, which regulates homocysteine levels. Homocysteine is an amino acid; in high concentrations, it damages blood vessel walls and increases clotting risk.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces enzyme activity by 40-70%. Your cells convert folate into active methyl donors at a fraction of the rate they should, leading to elevated homocysteine even if your dietary folate is adequate. Standard bloodwork often doesn’t catch this because lab ranges for homocysteine are wide; your level might be technically “normal” but still elevated enough to increase your cardiovascular risk.

You might feel inexplicable fatigue, brain fog, or anxiety. Your mood can be unstable. You might notice that B vitamin supplementation doesn’t give you the energy boost others describe. And despite eating plenty of leafy greens, your homocysteine drifts upward. People with MTHFR variants often discover that standard folic acid supplements make them feel worse, not better.

Your ACE gene encodes angiotensin-converting enzyme, which sits in your blood vessels and lungs. It catalyzes the conversion of angiotensin I (an inactive hormone) into angiotensin II (a powerful chemical that makes blood vessels contract). This is a critical control point: less ACE activity means lower blood pressure; higher ACE activity means tighter, more contracted vessels and higher baseline blood pressure.

The ACE I/D polymorphism determines how much enzyme your body produces. If you carry the D/D genotype, roughly 25% of the population, your body produces more ACE, meaning more angiotensin II is being generated from angiotensin I. Your blood vessels are under constant higher-tone contraction, and your kidneys retain more sodium and water, all pushing your baseline blood pressure upward. You don’t necessarily have hypertension by clinical standards, but you might run 5-15 mmHg higher than someone with the I/I variant.

You might notice that your blood pressure responds unpredictably to salt. You cut sodium and it barely budges. Or you eat salt and your pressure spikes dramatically. You might find that standard blood pressure advice (“just exercise more and reduce sodium”) isn’t moving the needle. People with D/D genotypes often benefit from ACE inhibitors or ARBs at lower doses than population averages suggest, or from aggressive mineral supplementation strategies.

Your NOS3 gene encodes endothelial nitric oxide synthase, an enzyme that produces nitric oxide (NO) in the lining of your blood vessels. Nitric oxide is a signaling molecule that tells blood vessel smooth muscle to relax, dilate, and improve blood flow. It’s one of the most important modulators of vascular tone in your body. Without adequate nitric oxide production, your vessels stay constricted, blood pressure climbs, and atherosclerosis accelerates.

The NOS3 Glu298Asp variant (rs1799983) impairs the enzyme’s ability to produce nitric oxide. Roughly 30-40% of the population carries this variant. Your blood vessels cannot relax as easily in response to exercise or stress, meaning your blood pressure stays elevated and your endothelial function deteriorates faster than someone without the variant. This is particularly damaging because nitric oxide is also anti-inflammatory and anti-thrombotic; low production means your arteries are stiffer and more prone to plaque accumulation.

You might notice that exercise doesn’t lower your blood pressure as much as you’d expect, or that you feel unusually short of breath during exertion. Your endothelial function might be poor on stress testing. People with NOS3 variants often show signs of vascular dysfunction years before blood pressure becomes frankly elevated. Standard blood pressure medications often don’t fully address the underlying endothelial dysfunction.

Your LPA gene controls the production of lipoprotein(a), often abbreviated Lp(a). Lp(a) is a lipoprotein particle very similar to LDL, but it carries an additional protein called apolipoprotein(a). Lp(a) is largely genetically determined; lifestyle changes have minimal impact on your levels. Unlike LDL, which most people can modify through diet and exercise, Lp(a) is written into your DNA.

Roughly 20% of the population carries genetic variants that produce high Lp(a) levels. Elevated Lp(a) is a potent independent cardiovascular risk factor, comparable to or exceeding the risk from high LDL cholesterol. Lp(a) is pro-inflammatory and pro-thrombotic: it promotes plaque formation and increases the likelihood that a clot will form on that plaque. It also interferes with fibrinolysis, the body’s ability to dissolve clots.

You might have normal LDL cholesterol but still have high cardiovascular risk. Standard cardiac risk calculators often underestimate your actual risk because they don’t account for Lp(a). If you’ve had a heart attack or stroke without obvious risk factors, or if heart disease runs in your family despite normal cholesterol, high Lp(a) may be the hidden culprit. People with elevated Lp(a) often discover their risk profile is far more serious than standard screening suggests.

Your PCSK9 gene encodes a protein that acts as a cellular recycling manager. Specifically, PCSK9 binds to LDL receptors on your cell surface (the structures that pull LDL cholesterol out of your bloodstream) and targets them for degradation. This is normally a controlled process: old receptors get destroyed and new ones are made. But if PCSK9 is overactive, it destroys receptors faster than your cells can replace them, leading to fewer receptors and less LDL clearance.

Gain-of-function variants in PCSK9, carried by roughly 1-3% of the population, make PCSK9 hyperactive. Your cells degrade LDL receptors at an accelerated rate, meaning you have fewer receptors available to pull LDL out of your blood, and your cholesterol climbs despite a clean diet or standard statin therapy. This is the mechanism behind some cases of familial hypercholesterolemia. In contrast, loss-of-function variants (much rarer) have the opposite effect: people with these variants have naturally low cholesterol and exceptional longevity.

You might notice that standard statins barely move your cholesterol, or that your cholesterol shoots back up as soon as you stop supplementation. Your cardiologist might escalate to higher statin doses with minimal effect. Or your cholesterol has been elevated since childhood despite a family history of longevity and health. People with gain-of-function PCSK9 variants often require next-generation medications to achieve adequate LDL control.